| Bioactivity | PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease[1]. | |||||||||
| Target | IC50: γ-secretase | |||||||||
| Invitro | In a cell-based assay, PF-06648671 reduces Aβ42 and Aβ40 , with concomitant increases in Aβ37 and Aβ38, without inhibiting the cleavage of Notch or other substrates[1]. | |||||||||
| In Vivo | PF-06648671 demonstrates reduces Aβ42 within the brain and CSF following acute oral administration in animals[1]. | |||||||||
| Name | PF-06648671 | |||||||||
| CAS | 1587727-31-8 | |||||||||
| Formula | C25H23ClF4N4O3 | |||||||||
| Molar Mass | 538.92 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Jae Eun Ahn, et al. Pharmacokinetic and Pharmacodynamic Effects of a γ-Secretase Modulator, PF-06648671, on CSF Amyloid-β Peptides in Randomized Phase I Studies. Clin Pharmacol Ther 2020 Jan;107(1):211-220. |
PF-06648671
CAS: 1587727-31-8 F: C25H23ClF4N4O3 W: 538.92
PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.